Pruritus, commonly known as itching, is a condition characterized by an uncomfortable sensation that triggers the urge to scratch. It affects approximately 39.8% of the global population. This condition presents a significant unmet clinical need, as current treatment options, such as antihistamines and corticosteroids, often provide limited relief. With rising cases linked to chronic conditions like eczema, kidney disease, and liver disorders, the demand for more effective therapies is growing. Furthermore, increasing research on novel treatments, such as biologics and JAK inhibitors, alongside advancements in personalized medicine, is expected to drive the pruritus drug pipeline. The focus on developing targeted therapies offers hope for improved outcomes in the future.
The Pruritus Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into pruritus therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pruritus. The pruritus report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pruritus pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pruritus treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pruritus.
Pruritus, or itching, is a common symptom of numerous conditions, including dermatologic, systemic, and neurological disorders. It occurs when sensory nerve fibers in the skin are activated, leading to discomfort and scratching. The pruritus drug pipeline focuses on innovative treatments targeting the underlying causes, such as inflammation or immune dysfunction, to provide better symptom relief and improve quality of life.
Pruritus is commonly treated with antihistamines, corticosteroids, and topical emollients. In cases of chronic or severe pruritus, therapies such as JAK inhibitors, biologics, and phototherapy are gaining attention. These treatments aim to reduce inflammation and modulate immune responses to alleviate itching effectively.
A 2024 article on pruritus epidemiology highlighted a global prevalence of 39.8%, with the highest rates observed in individuals aged 65 and older. Women were more affected than men, showing a prevalence of 40.7% compared to 38.9%. Regional variations included the highest prevalence in Africa at 45.7%, followed by East Asia at 40.2% and Latin America at 36.5%. Europe recorded the lowest prevalence at 35.9%, while North America had a prevalence of 41.2%. BRICS countries exhibited a higher prevalence of 40.3%, compared to 38.7% in developed nations.
This section of the report covers the analysis of pruritus drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total pruritus clinical trials.
The drug molecule categories covered under the pruritus pipeline analysis include small molecules, biologics, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug across various phases of clinical trials for pruritus.
The EMR pruritus drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pruritus clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pruritus. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pruritus drug candidates.
The Phase 3 study sponsored by Mirum Pharmaceuticals, Inc. aims to evaluate the safety and efficacy of maralixibat in pediatric and adult participants with cholestatic liver disease and refractory pruritus. The study, expected to be completed by February 2027, will enroll 90 participants across multiple global sites, including North America, Europe, the Middle East, and South America.
Tharimmune Inc. is sponsoring a Phase 2a study on the efficacy of TH104 in treating moderate to severe pruritus in primary biliary cholangitis (PBC) patients. The study will include 40 participants and is designed to evaluate TH104's effectiveness in managing pruritus. The study is expected to be completed by April 2026.
The clinical trial sponsored by Wayne State University aims to examine the efficacy of ondansetron in preventing pruritus in patients undergoing cesarean sections under spinal anesthesia with morphine. The Phase 1 study will assess different timings of ondansetron administration to reduce pruritus and postoperative nausea or vomiting. The study is expected to be completed by December 2025, with 66 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Pruritus Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for pruritus. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within pruritus pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share